Janssen and Legend Biotech have begun a rolling submission of a biologics license application for ciltacabtagene autoleucel, or cilta-cel, their chimeric antigen receptor T-cell therapy candidate. The partners are seeking approval as a treatment for adults with relapsed or refractory multiple myeloma.